Trial Profile
Research Project in association with Protocol WN25203 "CSF sample retention for biomarker assay development" [SUBSTUDY OF 700060548]
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
- Sponsors Roche
- 06 May 2014 New trial record